PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
237.14%
Some net income increase while VET is negative at -94.93%. John Neff would see a short-term edge over the struggling competitor.
41.11%
D&A growth well above VET's 4.01%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
354.84%
Well above VET's 67.22% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-136.96%
Both cut yoy SBC, with VET at -36.12%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-62.71%
Both reduce yoy usage, with VET at -4.36%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-132.76%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.71%
Both reduce yoy usage, with VET at -4.36%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
51.02%
Some yoy increase while VET is negative at -79.71%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
71.27%
Some CFO growth while VET is negative at -16.72%. John Neff would note a short-term liquidity lead over the competitor.
-1.90%
Negative yoy CapEx while VET is 53.58%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-120.27%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-155.56%
Both yoy lines negative, with VET at -436.74%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-30.76%
We reduce yoy invests while VET stands at 47.18%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-2505.00%
We cut debt repayment yoy while VET is 27.03%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
-59.25%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.